Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 1, 2010

LGC Creates Genomics Segment

  • U.K.-based diagnostic and analytical services company LGC established a genomics division, LGC Genomics. The new business will offer a range of nucleic acid sample extraction services and products along with next-generation sequencing and other genomic services, the firm claims.

    Offerings will include the genomics products and services acquired by LGC through its 2005 buy-out of Agowa. These products and services will be rebranded under the LGC Genomics umbrella.

    LGC says that establishing a dedicated genomics unit is part of a wider restructuring program designed to expand the firm’s operations. “Under the new brand, LGC Genomics will continue to advance the development and delivery of first-rate genomic services and products,” comments John McQuillian, the new division’s managing director. “Our aim is for LGC Genomics to become Europe’s leading genomics provider through organic growth and selected strategic acquisitions.”

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »